terbinafine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2597 91161-71-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terbinafine
  • terbinol
  • terbinafine hydrochloride
  • terbinafine HCl
A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails.
  • Molecular weight: 291.44
  • Formula: C21H25N
  • CLOGP: 5.96
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -5.60
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 92.64 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1992 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ageusia 358.71 15.80 123 10858 11460 50582683
Acute generalised exanthematous pustulosis 204.98 15.80 76 10905 8862 50585281
Subacute cutaneous lupus erythematosus 182.83 15.80 50 10931 2165 50591978
Dysgeusia 148.60 15.80 97 10884 38819 50555324
Rash pustular 105.55 15.80 43 10938 6438 50587705
Gamma-glutamyltransferase increased 99.00 15.80 68 10913 29555 50564588
Pruritus 96.98 15.80 199 10782 283369 50310774
Aspartate aminotransferase increased 91.33 15.80 98 10883 77900 50516243
Cutaneous lupus erythematosus 87.76 15.80 29 10952 2402 50591741
Toxic skin eruption 82.87 15.80 43 10938 11208 50582935
Erythema multiforme 82.59 15.80 40 10941 9010 50585133
Blood alkaline phosphatase increased 82.51 15.80 67 10914 37459 50556684
Alanine aminotransferase increased 74.87 15.80 94 10887 88265 50505878
Skin exfoliation 73.86 15.80 60 10921 33552 50560591
Pathogen resistance 73.44 15.80 32 10949 5657 50588486
Chromaturia 69.81 15.80 42 10939 14548 50579595
Rash 63.14 15.80 223 10758 437248 50156895
Somatic delusion 62.05 15.80 16 10965 550 50593593
Jaundice 61.94 15.80 49 10932 26380 50567763
Erythema 59.92 15.80 111 10870 146303 50447840
Urticaria 53.97 15.80 99 10882 129462 50464681
Hepatic function abnormal 50.96 15.80 48 10933 32633 50561510
Rash erythematous 48.34 15.80 48 10933 34804 50559339
Anosmia 43.96 15.80 20 10961 3911 50590232
Lip swelling 43.76 15.80 39 10942 24697 50569446
Rash maculo-papular 41.28 15.80 39 10942 26602 50567541
Skin lesion 41.18 15.80 39 10942 26688 50567455
Blood lactate dehydrogenase increased 41.03 15.80 34 10947 19528 50574615
Hepatitis 39.39 15.80 41 10940 31412 50562731
Blood bilirubin increased 38.76 15.80 41 10940 31997 50562146
Liver disorder 37.04 15.80 43 10938 37179 50556964
Photosensitivity reaction 34.75 15.80 26 10955 12885 50581258
Pustular psoriasis 34.53 15.80 17 10964 3964 50590179
Drug resistance 33.71 15.80 30 10951 18959 50575184
Oral discomfort 33.06 15.80 21 10960 7996 50586147
Abnormal faeces 30.78 15.80 16 10965 4180 50589963
Dermatitis bullous 30.11 15.80 19 10962 7154 50586989
Drug eruption 29.96 15.80 31 10950 23575 50570568
Gastrointestinal motility disorder 29.70 15.80 16 10965 4493 50589650
Drug intolerance 29.20 15.80 6 10975 219098 50375045
Dermatitis exfoliative 27.73 15.80 16 10965 5126 50589017
Weight decreased 27.73 15.80 108 10873 221137 50373006
Urine odour abnormal 27.08 15.80 16 10965 5357 50588786
Skin oedema 26.92 15.80 9 10972 772 50593371
Rash papular 26.62 15.80 22 10959 12582 50581561
Bilirubin conjugated increased 26.02 15.80 12 10969 2420 50591723
Drug-induced liver injury 25.54 15.80 31 10950 28064 50566079
Red blood cell count decreased 25.49 15.80 34 10947 33801 50560342
Hepatitis cholestatic 25.17 15.80 16 10965 6101 50588042
Drug interaction 24.65 15.80 97 10884 199524 50394619
Rash pruritic 24.37 15.80 40 10941 47806 50546337
Blood creatine phosphokinase increased 23.82 15.80 29 10952 26338 50567805
Face oedema 23.68 15.80 24 10957 17815 50576328
Erythema nodosum 23.36 15.80 13 10968 3890 50590253
Systemic lupus erythematosus rash 23.07 15.80 10 10971 1745 50592398
Drug ineffective 22.94 15.80 96 10885 819237 49774906
Rash papulosquamous 22.37 15.80 5 10976 92 50594051
Antinuclear antibody positive 22.37 15.80 15 10966 6257 50587886
Tinea infection 21.87 15.80 8 10973 895 50593248
Off label use 21.71 15.80 44 10937 474382 50119761
Musculoskeletal discomfort 21.54 15.80 21 10960 14877 50579266
Death 20.81 15.80 24 10957 325355 50268788
Rash macular 20.40 15.80 23 10958 19254 50574889
Hypotension 20.37 15.80 13 10968 235456 50358687
Respiratory gas exchange disorder 20.36 15.80 6 10975 340 50593803
Onychomycosis 20.28 15.80 13 10968 5029 50589114
Pythium insidiosum infection 20.23 15.80 3 10978 3 50594140
Blister 20.23 15.80 52 10929 85366 50508777
Maternal exposure during pregnancy 20.03 15.80 5 10976 159773 50434370
Decreased appetite 19.66 15.80 91 10890 200832 50393311
Eosinophilia 19.31 15.80 22 10959 18630 50575513
Abortion induced 19.09 15.80 16 10965 9328 50584815
Swollen tongue 18.90 15.80 27 10954 28603 50565540
Cheilitis 18.85 15.80 11 10970 3599 50590544
Liver function test abnormal 18.57 15.80 34 10947 44305 50549838
Hepatitis toxic 18.57 15.80 10 10971 2806 50591337
Toxicity to various agents 18.01 15.80 12 10969 212487 50381656
Pityriasis rosea 17.93 15.80 4 10977 73 50594070
Therapeutic product effect decreased 17.56 15.80 4 10977 136046 50458097
Fundoscopy abnormal 17.29 15.80 3 10978 13 50594130
Hepatic cytolysis 16.81 15.80 14 10967 8089 50586054
Pneumonia respiratory syncytial viral 16.65 15.80 6 10975 644 50593499
Fungal skin infection 15.88 15.80 10 10971 3749 50590394

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pathogen resistance 189.65 14.12 82 11258 8034 29555153
Aspartate aminotransferase increased 120.89 14.12 131 11209 59594 29503593
Gamma-glutamyltransferase increased 107.42 14.12 86 11254 26651 29536536
Drug resistance 96.71 14.12 74 11266 21466 29541721
Alanine aminotransferase increased 96.34 14.12 127 11213 70817 29492370
Ageusia 92.95 14.12 52 11288 8886 29554301
Chromaturia 80.51 14.12 54 11286 12748 29550439
Jaundice 76.91 14.12 74 11266 29222 29533965
Blood alkaline phosphatase increased 75.04 14.12 72 11268 28334 29534853
Acute generalised exanthematous pustulosis 73.50 14.12 38 11302 5545 29557642
Blood creatine phosphokinase increased 71.61 14.12 83 11257 40561 29522626
Symmetrical drug-related intertriginous and flexural exanthema 57.10 14.12 14 11326 215 29562972
Pruritus 52.54 14.12 129 11211 116720 29446467
Diaphragmatic spasm 51.40 14.12 11 11329 88 29563099
Faecal volume decreased 49.76 14.12 11 11329 104 29563083
Onychomycosis 48.68 14.12 21 11319 2041 29561146
Death 47.74 14.12 37 11303 342047 29221140
Liver disorder 46.08 14.12 55 11285 27694 29535493
Rash 45.71 14.12 168 11172 189651 29373536
Rash pustular 45.27 14.12 26 11314 4665 29558522
Blood lactate dehydrogenase increased 43.87 14.12 45 11295 19164 29544023
Liver function test abnormal 42.66 14.12 54 11286 28864 29534323
Blood bilirubin increased 38.88 14.12 56 11284 33837 29529350
Skin exfoliation 37.78 14.12 45 11295 22600 29540587
Hypotension 37.28 14.12 14 11326 194340 29368847
Rash erythematous 36.22 14.12 43 11297 21519 29541668
Swelling of eyelid 35.81 14.12 12 11328 582 29562605
Epstein-Barr virus antibody positive 34.94 14.12 10 11330 285 29562902
Impetigo 34.18 14.12 13 11327 912 29562275
Hepatic function abnormal 34.02 14.12 57 11283 39202 29523985
Erythema nodosum 33.88 14.12 13 11327 934 29562253
Treatment failure 33.85 14.12 55 11285 36884 29526303
Hepatic lesion 31.85 14.12 18 11322 3132 29560055
Toxicity to various agents 30.88 14.12 14 11326 173647 29389540
Erythema 28.30 14.12 78 11262 75528 29487659
Eczema 27.33 14.12 30 11310 13796 29549391
Erythema multiforme 27.14 14.12 23 11317 7694 29555493
Drug-induced liver injury 26.63 14.12 37 11303 21618 29541569
Rosacea 26.24 14.12 11 11329 996 29562191
Cutaneous lupus erythematosus 26.07 14.12 10 11330 718 29562469
Tongue discomfort 25.78 14.12 9 11331 494 29562693
Off label use 23.74 14.12 50 11290 300750 29262437
Antinuclear antibody positive 23.30 14.12 11 11329 1319 29561868
Dysgeusia 22.47 14.12 35 11305 22639 29540548
Deficiency of bile secretion 22.46 14.12 4 11336 10 29563177
Hairy cell leukaemia 21.93 14.12 5 11335 55 29563132
Scedosporium infection 21.89 14.12 9 11331 776 29562411
Choluria 21.79 14.12 6 11334 148 29563039
Erythrodermic psoriasis 21.72 14.12 9 11331 791 29562396
Cholestasis 21.58 14.12 35 11305 23427 29539760
Hepatitis cholestatic 21.13 14.12 19 11321 6874 29556313
Myoglobin urine present 21.00 14.12 6 11334 170 29563017
Myalgia 20.75 14.12 69 11271 73950 29489237
Blister 20.11 14.12 31 11309 19875 29543312
Urticaria 20.05 14.12 56 11284 54604 29508583
Skin warm 19.81 14.12 11 11329 1849 29561338
Biliary obstruction 19.68 14.12 12 11328 2402 29560785
Lymphocyte stimulation test positive 19.42 14.12 8 11332 693 29562494
Rhabdomyolysis 19.15 14.12 59 11281 60749 29502438
Dermatitis exfoliative 18.31 14.12 17 11323 6408 29556779
Completed suicide 18.13 14.12 6 11334 90240 29472947
Hodgkin's disease 17.92 14.12 8 11332 844 29562343
Discomfort 17.81 14.12 25 11315 14738 29548449
Dermatitis contact 17.32 14.12 12 11328 2980 29560207
Dermatitis 17.31 14.12 18 11322 7780 29555407
Benign breast neoplasm 16.99 14.12 3 11337 7 29563180
Neutrophil percentage decreased 16.89 14.12 6 11334 347 29562840
Product dispensing error 16.59 14.12 15 11325 5465 29557722
Pneumonia 16.58 14.12 65 11275 320107 29243080
Product substitution issue 16.58 14.12 19 11321 9153 29554034
Pityriasis rosea 16.46 14.12 4 11336 59 29563128
Vitamin E deficiency 16.45 14.12 3 11337 9 29563178
Malaise 16.40 14.12 111 11229 159491 29403696
Eyelid pain 16.34 14.12 4 11336 61 29563126
Periorbital oedema 16.22 14.12 12 11328 3303 29559884
Intertrigo 15.94 14.12 5 11335 196 29562991
Chronic spontaneous urticaria 15.72 14.12 4 11336 72 29563115
Drug eruption 15.42 14.12 25 11315 16716 29546471
Hepatocellular carcinoma 15.18 14.12 16 11324 7022 29556165
Nail discolouration 15.17 14.12 7 11333 797 29562390
Neuropsychiatric symptoms 14.92 14.12 6 11334 488 29562699
Skin plaque 14.87 14.12 12 11328 3750 29559437
Skin lesion 14.81 14.12 26 11314 18546 29544641
Hepatic enzyme increased 14.80 14.12 37 11303 33762 29529425
Needle issue 14.54 14.12 13 11327 4670 29558517
Trichophytosis 14.42 14.12 5 11335 269 29562918

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ageusia 315.21 12.82 128 19288 13685 64465631
Pathogen resistance 261.60 12.82 109 19307 12434 64466882
Acute generalised exanthematous pustulosis 227.08 12.82 102 19314 13956 64465360
Aspartate aminotransferase increased 165.77 12.82 192 19224 119596 64359720
Subacute cutaneous lupus erythematosus 163.37 12.82 53 19363 2972 64476344
Gamma-glutamyltransferase increased 154.02 12.82 123 19293 48387 64430929
Chromaturia 141.65 12.82 87 19329 22524 64456792
Alanine aminotransferase increased 139.87 12.82 190 19226 138841 64340475
Rash pustular 132.39 12.82 63 19353 9822 64469494
Drug resistance 131.04 12.82 98 19318 35004 64444312
Blood alkaline phosphatase increased 122.43 12.82 115 19301 56164 64423152
Pruritus 118.24 12.82 278 19138 312122 64167194
Jaundice 116.95 12.82 105 19311 48407 64430909
Dysgeusia 98.24 12.82 94 19322 46953 64432363
Skin exfoliation 94.33 12.82 90 19326 44795 64434521
Cutaneous lupus erythematosus 94.01 12.82 34 19382 2648 64476668
Rash 91.38 12.82 324 19092 458225 64021091
Blood creatine phosphokinase increased 87.91 12.82 98 19318 58460 64420856
Rash erythematous 81.04 12.82 86 19330 48547 64430769
Erythema multiforme 79.89 12.82 53 19363 15648 64463668
Toxic skin eruption 79.08 12.82 57 19359 19227 64460089
Erythema 67.92 12.82 164 19252 186906 64292410
Blood lactate dehydrogenase increased 65.11 12.82 64 19352 33014 64446302
Somatic delusion 62.53 12.82 18 19398 672 64478644
Hepatic function abnormal 60.22 12.82 85 19331 64228 64415088
Blood bilirubin increased 58.29 12.82 79 19337 57474 64421842
Hypotension 56.58 12.82 22 19394 380952 64098364
Urticaria 56.53 12.82 132 19284 147185 64332131
Liver function test abnormal 54.86 12.82 78 19338 59323 64419993
Diaphragmatic spasm 53.84 12.82 11 19405 90 64479226
Liver disorder 53.67 12.82 73 19343 53278 64426038
Symmetrical drug-related intertriginous and flexural exanthema 50.97 12.82 15 19401 606 64478710
Toxicity to various agents 50.75 12.82 23 19393 363490 64115826
Faecal volume decreased 48.93 12.82 11 19405 147 64479169
Onychomycosis 48.66 12.82 26 19390 5170 64474146
Completed suicide 47.13 12.82 6 19410 224408 64254908
Skin lesion 46.26 12.82 56 19360 36426 64442890
Death 43.28 12.82 49 19367 482656 63996660
Pustular psoriasis 42.20 12.82 22 19394 4161 64475155
Lip swelling 40.49 12.82 49 19367 31858 64447458
Off label use 38.01 12.82 84 19332 632722 63846594
Drug-induced liver injury 37.43 12.82 58 19358 47585 64431731
Dermatitis exfoliative 36.61 12.82 28 19388 10324 64468992
Anosmia 35.56 12.82 20 19396 4397 64474919
Photosensitivity reaction 35.45 12.82 35 19381 18138 64461178
Oral discomfort 34.81 12.82 25 19391 8381 64470935
Cholestasis 34.38 12.82 54 19362 44818 64434498
Drug eruption 34.17 12.82 48 19368 36088 64443228
Antinuclear antibody positive 33.99 12.82 22 19394 6228 64473088
Scedosporium infection 33.39 12.82 13 19403 1241 64478075
Urine odour abnormal 32.76 12.82 20 19396 5116 64474200
Pityriasis rosea 32.06 12.82 8 19408 171 64479145
Erythema nodosum 31.88 12.82 18 19398 3986 64475330
Myalgia 31.34 12.82 112 19304 158505 64320811
Hepatitis cholestatic 30.64 12.82 27 19389 12128 64467188
Hepatic lesion 30.45 12.82 20 19396 5804 64473512
Epstein-Barr virus antibody positive 30.14 12.82 10 19406 601 64478715
Rash maculo-papular 29.85 12.82 52 19364 46974 64432342
Blister 29.34 12.82 71 19345 80896 64398420
Drug abuse 29.12 12.82 3 19413 132371 64346945
Eczema 28.88 12.82 40 19376 29680 64449636
Impetigo 28.82 12.82 13 19403 1793 64477523
Periorbital oedema 28.32 12.82 21 19395 7393 64471923
Skin oedema 28.22 12.82 12 19404 1436 64477880
Red blood cell count decreased 27.51 12.82 51 19365 48335 64430981
Hepatitis 27.12 12.82 49 19367 45533 64433783
Dermatitis bullous 26.89 12.82 25 19391 12029 64467287
Decreased appetite 26.64 12.82 160 19256 281129 64198187
Swelling of eyelid 26.41 12.82 13 19403 2179 64477137
Drug intolerance 26.03 12.82 12 19404 187980 64291336
Abnormal faeces 25.58 12.82 18 19398 5841 64473475
Hepatitis toxic 25.20 12.82 16 19400 4384 64474932
Systemic lupus erythematosus rash 25.12 12.82 11 19405 1414 64477902
Skin plaque 24.85 12.82 21 19395 8919 64470397
Rash macular 24.71 12.82 33 19383 23652 64455664
Rhabdomyolysis 24.67 12.82 72 19344 91654 64387662
Face oedema 23.57 12.82 33 19383 24728 64454588
Dermatitis 23.38 12.82 28 19388 18001 64461315
Gastrointestinal motility disorder 22.82 12.82 16 19400 5163 64474153
Hairy cell leukaemia 22.66 12.82 5 19411 61 64479255
Tinea infection 21.61 12.82 9 19407 1023 64478293
Antiphospholipid antibodies positive 21.59 12.82 8 19408 667 64478649
Pneumonia 21.57 12.82 91 19325 559485 63919831
Lymphocyte stimulation test positive 21.01 12.82 9 19407 1097 64478219
Neutrophil percentage decreased 20.92 12.82 8 19408 728 64478588
Treatment failure 20.16 12.82 79 19337 116737 64362579
Contraindicated product administered 20.11 12.82 4 19412 107825 64371491
Hodgkin's disease 19.88 12.82 8 19408 833 64478483
Rash pruritic 19.38 12.82 49 19367 57355 64421961
Maternal exposure during pregnancy 19.09 12.82 3 19413 95881 64383435
Rash papulosquamous 19.00 12.82 5 19411 133 64479183
Faeces pale 18.97 12.82 11 19405 2560 64476756
Neuropsychiatric symptoms 18.81 12.82 8 19408 958 64478358
Anal haemorrhage 18.76 12.82 12 19404 3328 64475988
Tinea pedis 18.42 12.82 10 19406 2051 64477265
Choluria 18.41 12.82 6 19410 341 64478975
Stevens-Johnson syndrome 18.10 12.82 35 19381 34214 64445102
Rash papular 18.09 12.82 24 19392 17089 64462227
Pythium insidiosum infection 18.03 12.82 3 19413 6 64479310
Erythrodermic psoriasis 17.95 12.82 9 19407 1570 64477746
Malaise 17.86 12.82 190 19226 396057 64083259
Musculoskeletal discomfort 17.47 12.82 23 19393 16254 64463062
Biliary obstruction 17.17 12.82 12 19404 3852 64475464
Neutrophilia 17.13 12.82 15 19401 6679 64472637
Skin warm 17.07 12.82 14 19402 5703 64473613
Septal panniculitis 16.84 12.82 4 19412 69 64479247
Eosinophil count increased 16.81 12.82 21 19395 14091 64465225
Seborrhoeic dermatitis 16.71 12.82 9 19407 1817 64477499
Infusion related reaction 16.63 12.82 15 19401 164452 64314864
Pustule 16.16 12.82 8 19408 1357 64477959
Rosacea 16.11 12.82 11 19405 3402 64475914
Mean cell volume abnormal 15.99 12.82 6 19410 518 64478798
Weight decreased 15.79 12.82 143 19273 285596 64193720
Cardio-respiratory arrest 15.74 12.82 5 19411 98388 64380928
Tongue discomfort 15.54 12.82 9 19407 2090 64477226
Vitamin E deficiency 15.49 12.82 3 19413 18 64479298
Rheumatoid arthritis 15.43 12.82 16 19400 164278 64315038
Erectile dysfunction 15.38 12.82 19 19397 12608 64466708
Dehydration 15.37 12.82 26 19390 216737 64262579
Urinary tract infection 15.32 12.82 29 19387 231567 64247749
Myoglobin urine present 15.30 12.82 6 19410 584 64478732
Therapeutic product effect decreased 15.00 12.82 8 19408 115343 64363973
Intertrigo 14.99 12.82 6 19410 616 64478700
Febrile neutropenia 14.74 12.82 21 19395 187636 64291680
Tinea versicolour 14.69 12.82 5 19411 325 64478991
Eye swelling 14.61 12.82 25 19391 22256 64457060
Trichophytosis 14.56 12.82 5 19411 334 64478982
Erythema annulare 14.31 12.82 4 19412 134 64479182
Fungal skin infection 14.16 12.82 12 19404 5113 64474203
Drug reaction with eosinophilia and systemic symptoms 14.04 12.82 42 19374 54175 64425141
Prostatic haemorrhage 14.01 12.82 4 19412 145 64479171
Respiratory gas exchange disorder 13.79 12.82 6 19410 759 64478557
Hepatic cytolysis 13.78 12.82 19 19397 14030 64465286
Hypokalaemia 13.71 12.82 10 19406 121893 64357423
Deficiency of bile secretion 13.64 12.82 3 19413 36 64479280
Intentional overdose 13.64 12.82 5 19411 89939 64389377
Vomiting 13.43 12.82 104 19312 551013 63928303
Dermatitis contact 13.38 12.82 15 19401 8985 64470331
Intentional product use issue 13.33 12.82 6 19410 95358 64383958
Laryngeal pain 13.12 12.82 12 19404 5656 64473660
Prothrombin time shortened 13.02 12.82 9 19407 2840 64476476
Fall 13.01 12.82 73 19343 416753 64062563
Pulmonary embolism 12.92 12.82 15 19401 146341 64332975

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AE15 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Other antifungals for topical use
ATC D01BA02 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR SYSTEMIC USE
Antifungals for systemic use
FDA CS M0000751 Allylamine
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:50183 P450 inhibitors
CHEBI has role CHEBI:59285 squalene monooxygenase inhibitors
CHEBI has role CHEBI:83317 sterol biosynthesis inhibitors
FDA EPC N0000175874 Allylamine Antifungal

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea capitis indication 5441008
Tinea pedis indication 6020002 DOID:12403
Pityriasis versicolor indication 56454009 DOID:9060
Tinea corporis indication 84849002
Tinea cruris indication 399029005
Onychomycosis due to dermatophyte indication 402134005
Onychomycosis of fingernails indication 403058003
Onychomycosis of toenails indication 403059006
Candidiasis of skin off-label use 49883006
Chromoblastomycosis off-label use 187079000
Alcoholism contraindication 7200002
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Otitis externa caused by yeast, Malassezia pachydermatis Indication

🐶 Veterinary products

ProductApplicantIngredients
Osurnia Dechra, Ltd. 3
CLARO Elanco US Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.02 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.63 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.39 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.70 DRUG MATRIX
Squalene monooxygenase Enzyme Ki 7.52 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.67 DRUG MATRIX
Squalene epoxidase Enzyme INHIBITOR CHEMBL CHEMBL
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 7.66 DRUG MATRIX
Squalene monooxygenase Enzyme IC50 4.03 CHEMBL

External reference:

IDSource
4023600 VUID
N0000021605 NUI
D02219 KEGG_DRUG
78628-80-5 SECONDARY_CAS_RN
4020792 VANDF
4023600 VANDF
C0076110 UMLSCUI
CHEBI:9448 CHEBI
CHEMBL822 ChEMBL_ID
DB00857 DRUGBANK_ID
CHEMBL1200832 ChEMBL_ID
D000077291 MESH_DESCRIPTOR_UI
1549008 PUBCHEM_CID
5657 INN_ID
G7RIW8S0XP UNII
235838 RXNORM
116863 MMSL
5547 MMSL
d04012 MMSL
004051 NDDF
004052 NDDF
108925005 SNOMEDCT_US
108927002 SNOMEDCT_US
373450007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LamisilAT Jock Itch HUMAN OTC DRUG LABEL 1 0067-3999 CREAM 10 mg TOPICAL NDA 13 sections
LAMISILAT HUMAN OTC DRUG LABEL 1 0067-6296 AEROSOL, SPRAY 0.84 g TOPICAL NDA 13 sections
LAMISILAT HUMAN OTC DRUG LABEL 1 0067-6297 AEROSOL, SPRAY 0.84 g TOPICAL NDA 13 sections
Lamisil AT HUMAN OTC DRUG LABEL 1 0067-8100 CREAM 1 g TOPICAL ANDA 14 sections
Lamisil ATfor Jock Itch HUMAN OTC DRUG LABEL 1 0067-8114 CREAM 1 g TOPICAL ANDA 14 sections
Walgreens Athletes Foot HUMAN OTC DRUG LABEL 1 0363-2080 CREAM 1 g TOPICAL ANDA 14 sections
Terbinafine Hydrochloride HUMAN OTC DRUG LABEL 1 0363-2083 CREAM 1 g TOPICAL ANDA 14 sections
Athletes Foot HUMAN OTC DRUG LABEL 1 11673-080 CREAM 1 g TOPICAL ANDA 14 sections
athletes foot HUMAN OTC DRUG LABEL 1 11673-401 CREAM 10 mg TOPICAL NDA 7 sections
Athletes Foot HUMAN OTC DRUG LABEL 1 11822-0080 CREAM 1 g TOPICAL ANDA 14 sections
Terbinafine Human Prescription Drug Label 1 16714-795 TABLET 250 mg ORAL ANDA 27 sections
Athletes Foot HUMAN OTC DRUG LABEL 1 21130-080 CREAM 1 g TOPICAL ANDA 13 sections
Terbinafine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-630 TABLET 250 mg ORAL ANDA 19 sections
Good Neighbor Pharmacy HUMAN OTC DRUG LABEL 1 24385-524 CREAM 1 g TOPICAL ANDA 14 sections
Kroger Antifungal HUMAN OTC DRUG LABEL 1 30142-080 CREAM 1 g TOPICAL ANDA 14 sections
Terbinafine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 31722-209 TABLET 250 1 ORAL ANDA 26 sections
Athletes Foot HUMAN OTC DRUG LABEL 1 36800-080 CREAM 1 g TOPICAL ANDA 14 sections
Shopko Athletes Foot HUMAN OTC DRUG LABEL 1 37012-080 CREAM 1 g TOPICAL ANDA 14 sections
Athletes Foot HUMAN OTC DRUG LABEL 1 37808-080 CREAM 1 g TOPICAL ANDA 14 sections
athletes foot HUMAN OTC DRUG LABEL 1 41163-080 CREAM 1 g TOPICAL ANDA 14 sections
ShopRite HUMAN OTC DRUG LABEL 1 41190-083 CREAM 1 g TOPICAL ANDA 14 sections
Antifungal HUMAN OTC DRUG LABEL 1 41250-080 CREAM 1 g TOPICAL ANDA 14 sections
Antifungal Foot HUMAN OTC DRUG LABEL 1 41520-080 CREAM 1 g TOPICAL ANDA 14 sections
terbinafine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42043-410 TABLET 250 mg ORAL ANDA 20 sections
Terbinafine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-598 TABLET 250 mg ORAL ANDA 31 sections
Terbinafine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-906 TABLET 250 mg ORAL ANDA 33 sections
Terbinafine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-893 TABLET 250 mg ORAL ANDA 31 sections
equate Athletes Foot HUMAN OTC DRUG LABEL 1 49035-080 CREAM 1 g TOPICAL ANDA 14 sections
Athletes Foot HUMAN OTC DRUG LABEL 1 49348-790 CREAM 1 g TOPICAL ANDA 13 sections
Silka Antifungal HUMAN OTC DRUG LABEL 1 50066-080 CREAM 1 g TOPICAL ANDA 14 sections